Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCN19-overexpressed MSCs for Refractory Type 2 Diabetes Mellitus
NCT06727721Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells in type 2 diabetes mellitus (T2DM) (3 arms). Primary endpoint: Daily insulin dose at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06727721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727721.